港股異動丨美中嘉和一度漲超12% 股價較年內低點已反彈超42%
美中嘉和(2453.HK)今日盤中一度大漲12.46%至7.49港元,股價較6月初盤中觸及的年內低點5.25港元已反彈超42%。美中嘉和公告,公司子公司廣州泰和腫瘤醫院於2025年7月11日,成功完成全國首例脈絡膜惡性黑色素瘤質子治療。廣州泰和腫瘤醫院運用先進的質子治療筆形束掃描技術,結合實時影像引導系統,實現對腫瘤靶區的高劑量精準照射,同時最大限度地保護鄰近重要結構,使患者免於眼球摘除。作爲國內首家開展該病種質子治療的醫療機構,廣州泰和腫瘤醫院填補了該領域的空白,爲脈絡膜惡性黑色素瘤患者提供了保眼治療新選擇。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.